Fulltext

Sequence analysis and high-throughput immunhistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays

Pache, Mona ; Glatz, Katharina ; Bösch, Doris ; Dirnhofer, Stephan ; Mirlacher, Martina ; Simon, Ronald ; Schraml, Peter ; Rufle, Alex ; Flammer, Josef ; Sauter, Guido ; Meyer, Peter

In: Virchows Archiv, 2003, vol. 443, no. 6, p. 741-744

Zum persönliche Liste hinzufügen
    Titel
    • Sequence analysis and high-throughput immunhistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays
    Autor
    • Pache, Mona. University Eye Clinic of Basel, Basel, Switzerland
    • Glatz, Katharina. Institute of Pathology, University of Basel, Basel, Switzerland
    • Bösch, Doris. University Eye Clinic of Basel, Basel, Switzerland
    • Dirnhofer, Stephan. Institute of Pathology, University of Basel, Basel, Switzerland
    • Mirlacher, Martina. Institute of Pathology, University of Basel, Basel, Switzerland
    • Simon, Ronald. Institute of Pathology, University of Basel, Basel, Switzerland
    • Schraml, Peter. Institute of Pathology, University of Basel, Basel, Switzerland
    • Rufle, Alex. Institute of Pathology, University of Basel, Basel, Switzerland
    • Flammer, Josef. University Eye Clinic of Basel, Basel, Switzerland
    • Sauter, Guido. Institute of Pathology, University of Basel, Basel, Switzerland
    • Meyer, Peter. University Eye Clinic of Basel, Basel, Switzerland
    Dokumententyp
    • Postprint
    OAI-PMH-ID
    • oai:doc.rero.ch:310443
    Summary
    We aimed to immunohistochemically examine the expression of KIT (CD 117) in human posterior uveal melanoma and to analyze KIT-positive tumors for gene mutations. Brought into a tissue microarray (TMA) format were 101 formalin-fixed, paraffin-embedded posterior uveal melanomas. Immunhistochemistry was performed using the polyclonal anti-CD117 antibody from Dako (A4502). In ten selected KIT-positive tumors, exons 2, 8, 9, 11, 13 and 17 were sequenced. Of the 101 cases, 89 (88%) could be evaluated on the TMAs. Immunohistochemistry for CD 117 was weakly positive in 5 cases (6%), moderately positive in 10 cases (12%) and strongly positive in 57 cases (69%). No KIT mutations were detected in the analyzed exons. In conclusion, human posterior uveal melanoma frequently expresses CD117 at high levels. Although KIT mutations could not be found, it appears justified to investigate the utility of imatinib mesylate in the treatment of these patients